Shots:

• The P-IIb study will evaluate three dose levels of ION449 (once a month- SC) vs PBO and will enroll ~108 patients aged 18-75yrs.- who have LDL-C levels b/w 70-190 mg/dL and are receiving moderate/ high-intensity statin therapy
• The P-I study results demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90% and ~70% respectively
• AstraZeneca granted $20M as a milestone to Ionis for the initiation of the P-II study. ION449 is antisense therapy designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting PCSK9

 ­ Ref: PRNewswire | Image: Al Jazeera